Clinical data from 48 patients of ALK fusion advanced or metastatic NSCLC receiving firstline ALK inhibitor treatment (35 in the crizotinib group and 13 in the ceritinib group) were extracted from the Chang Gung Research Database. This evidence concerns the gene ALK and non-small cell lung carcinoma.